Free tool
FAERS Monitor: Pataday Twice Daily Relief
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020688 or its brand name (Pataday Twice Daily Relief, Olopatadine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
4,235
Serious
1,367
32% of reports
Hospitalization
787
Death reported
195
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure1,934
- drug ineffective315
- headache123
- nausea117
- diarrhoea114
- fatigue104
- pyrexia104
- pneumonia103
- malaise99
- rash98
- pruritus95
- dyspnoea92
- pain92
- cough89
- eye irritation85
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 17 |
| 2009 | 18 |
| 2010 | 26 |
| 2011 | 25 |
| 2012 | 24 |
| 2013 | 30 |
| 2014 | 29 |
| 2015 | 49 |
| 2016 | 82 |
| 2017 | 91 |
| 2018 | 131 |
| 2019 | 191 |
| 2020 | 1,938 |
| 2021 | 365 |
| 2022 | 216 |
| 2023 | 220 |
| 2024 | 244 |
| 2025 | 255 |
| 2026 | 255 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,924 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 1,934 | 118.7 | 114.8 | 221,181 |
| eye irritationSignal | 85 | 7.3 | 5.9 | 460 |
| pneumonia | 103 | 1.6 | 1.3 | 22 |
| cough | 89 | 1.6 | 1.3 | 18 |
| pyrexia | 104 | 1.5 | 1.2 | 17 |
| pruritus | 95 | 1.2 | 1.0 | 4 |
| drug ineffective | 315 | 1.2 | 1.1 | 10 |
| malaise | 99 | 1.1 | 0.9 | 1 |
| rash | 98 | 1.1 | 0.9 | 1 |
| headache | 123 | 1.0 | 0.8 | 0 |
| diarrhoea | 114 | 0.9 | 0.7 | 2 |
| dyspnoea | 92 | 0.8 | 0.7 | 4 |
| pain | 92 | 0.7 | 0.6 | 8 |
| nausea | 117 | 0.7 | 0.6 | 11 |
| fatigue | 104 | 0.7 | 0.5 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.